Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B
NCT06092333Phase 2
Key facts
- Status
- Active, not recruiting
- Start
- Jan 2025
- Primary completion
- Feb 2028
- Countries
- 1
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Drugs
- elebsiran
- Conditions
- Chronic Hepatitis B (CHB)
01
Overview
Phase 2, open-label, single-arm trial of elebsiran in Chronic Hepatitis B (CHB), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Primary endpoint: Decline in log quantitative HBsAg level at 60 weeks. Started Jan 2025; status: active, not recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Single arm, open label
All participants receive the sequential regimen of VIR-2218 and peginterferon alfa-2a.
03
Who it enrols
Adults aged 18-65 with untreated, HBeAg-negative chronic hepatitis B, low viral load, and no cirrhosis.
04
Endpoints
Primary
Decline in log quantitative HBsAg level
Secondary
Changes in innate and adaptive host immune responses to HBV
HBV DNA <10 IU/ml
Functional cure
Safety and tolerability
Beyond the preview
Go deeper on NCT06092333.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06092333.